When should factorial designs be used for late-phase randomised controlled trials?

被引:0
|
作者
White, Ian R. [1 ,2 ]
Szubert, Alexander J. [1 ]
Choodari-Oskooei, Babak [1 ]
Walker, A. Sarah [1 ]
Parmar, Mahesh K. B. [1 ]
机构
[1] UCL, MRC Clin Trials Unit, London, England
[2] UCL, MRC Clin Trials Unit, 2nd Floor, 90 High Holborn, London WC1V 6LJ, England
关键词
Randomised controlled trial; clinical trial; design; factorial; CLINICAL-TRIALS; CHALLENGES; MULTIARM; THERAPY;
D O I
10.1177/17407745231206261
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Background: A 2 x 2 factorial design evaluates two interventions (A versus control and B versus control) by randomising to control, A-only, B-only or both A and B together. Extended factorial designs are also possible (e.g. 3 x 3 or 2 x 2 x 2). Factorial designs often require fewer resources and participants than alternative randomised controlled trials, but they are not widely used. We identified several issues that investigators considering this design need to address, before they use it in a late-phase setting. Methods: We surveyed journal articles published in 2000-2022 relating to designing factorial randomised controlled trials. We identified issues to consider based on these and our personal experiences. Results: We identified clinical, practical, statistical and external issues that make factorial randomised controlled trials more desirable. Clinical issues are (1) interventions can be easily co-administered; (2) risk of safety issues from co-administration above individual risks of the separate interventions is low; (3) safety or efficacy data are wanted on the combination intervention; (4) potential for interaction (e.g. effect of A differing when B administered) is low; (5) it is important to compare interventions with other interventions balanced, rather than allowing randomised interventions to affect the choice of other interventions; (6) eligibility criteria for different interventions are similar. Practical issues are (7) recruitment is not harmed by testing many interventions; (8) each intervention and associated toxicities is unlikely to reduce either adherence to the other intervention or overall follow-up; (9) blinding is easy to implement or not required. Statistical issues are (10) a suitable scale of analysis can be identified; (11) adjustment for multiplicity is not required; (12) early stopping for efficacy or lack of benefit can be done effectively. External issues are (13) adequate funding is available and (14) the trial is not intended for licensing purposes. An overarching issue (15) is that factorial design should give a lower sample size requirement than alternative designs. Across designs with varying non-adherence, retention, intervention effects and interaction effects, 2 x 2 factorial designs require lower sample size than a three-arm alternative when one intervention effect is reduced by no more than 24%-48% in the presence of the other intervention compared with in the absence of the other intervention. Conclusions: Factorial designs are not widely used and should be considered more often using our issues to consider. Low potential for at most small to modest interaction is key, for example, where the interventions have different mechanisms of action or target different aspects of the disease being studied.
引用
收藏
页码:162 / 170
页数:9
相关论文
共 50 条
  • [21] When and how should multiple imputation be used for handling missing data in randomised clinical trials – a practical guide with flowcharts
    Janus Christian Jakobsen
    Christian Gluud
    Jørn Wetterslev
    Per Winkel
    BMC Medical Research Methodology, 17
  • [22] A Systematic Review of Adaptive Seamless Clinical Trials for Late-Phase Oncology Development
    Broglio, Kristine
    Cooner, Freda
    Wu, Yujun
    Xiao, Mike
    Xue, X. Q.
    Lowen, Marina
    Ikhapoh, Izuagie
    He, Philip
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (05) : 917 - 929
  • [23] The stepped wedge cluster randomised trial: what it is and when it should be used
    Campbell, Michael J.
    Hemming, Karla
    Taljaard, Monica
    MEDICAL JOURNAL OF AUSTRALIA, 2019, 210 (06) : 253 - +
  • [24] Differential dropout and bias in randomised controlled trials: when it matters and when it may not
    Bell, Melanie L.
    Kenward, Michael G.
    Fairclough, Diane L.
    Horton, Nicholas J.
    BMJ-BRITISH MEDICAL JOURNAL, 2013, 346
  • [25] Randomised controlled trials in cystic fibrosis: what, when and how?
    Sly, P. D.
    Ware, R. S.
    de Klerk, N.
    Stick, S. M.
    EUROPEAN RESPIRATORY JOURNAL, 2011, 37 (05) : 991 - 993
  • [26] Patients should be informed when AI systems are used in clinical trials
    Subha Perni
    Lisa Soleymani Lehmann
    Danielle S. Bitterman
    Nature Medicine, 2023, 29 : 1890 - 1891
  • [27] Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials
    Kane, John M.
    Durgam, Suresh
    Satlin, Andrew
    Vanover, Kimberly E.
    Chen, Richard
    Davis, Robert
    Mates, Sharon
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (05) : 244 - 250
  • [28] Patients should be informed when AI systems are used in clinical trials
    Perni, Subha
    Lehmann, Lisa Soleymani
    Bitterman, Danielle S.
    NATURE MEDICINE, 2023, 29 (08) : 1890 - 1891
  • [30] Valuations of experimental designs in proteomic biomarker experiments and traditional randomised controlled trials
    Helgesson, Claes-Fredrik
    Lee, Francis
    Linden, Lisa
    JOURNAL OF CULTURAL ECONOMY, 2016, 9 (02) : 157 - 172